Q3 2024 EPS Estimates for Humana Inc. (NYSE:HUM) Reduced by Leerink Partnrs

Humana Inc. (NYSE:HUM - Free Report) - Leerink Partnrs reduced their Q3 2024 earnings per share (EPS) estimates for Humana in a note issued to investors on Wednesday, April 24th. Leerink Partnrs analyst W. Mayo now forecasts that the insurance provider will post earnings per share of $4.08 for the quarter, down from their prior forecast of $4.38. The consensus estimate for Humana's current full-year earnings is $16.08 per share. Leerink Partnrs also issued estimates for Humana's Q4 2024 earnings at ($1.86) EPS, Q1 2025 earnings at $8.76 EPS, Q3 2025 earnings at $5.75 EPS, Q4 2025 earnings at ($0.56) EPS and FY2025 earnings at $22.16 EPS.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.12 by $1.11. The firm had revenue of $29.61 billion for the quarter, compared to analysts' expectations of $28.52 billion. Humana had a net margin of 1.82% and a return on equity of 17.76%. The company's revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter last year, the business posted $9.38 earnings per share.

Other equities research analysts also recently issued reports about the company. Stephens decreased their price objective on Humana from $550.00 to $430.00 and set an "overweight" rating on the stock in a research report on Friday, January 26th. Truist Financial restated a "hold" rating and issued a $550.00 target price on shares of Humana in a report on Friday, January 19th. TD Cowen cut their price target on shares of Humana from $427.00 to $396.00 and set a "buy" rating on the stock in a report on Tuesday, April 2nd. Argus lowered Humana from a "buy" rating to a "hold" rating in a research note on Wednesday, March 13th. Finally, Royal Bank of Canada cut their price target on shares of Humana from $415.00 to $353.00 and set an "outperform" rating on the stock in a report on Thursday. Eleven equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $424.50.

Humana Price Performance

Shares of NYSE:HUM traded down $2.75 during mid-day trading on Monday, reaching $303.15. The stock had a trading volume of 1,654,862 shares, compared to its average volume of 1,990,798. The business's 50 day moving average price is $326.86 and its 200 day moving average price is $393.28. Humana has a 1 year low of $299.23 and a 1 year high of $541.21. The company has a market cap of $36.53 billion, a P/E ratio of 18.88, a price-to-earnings-growth ratio of 1.79 and a beta of 0.45. The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.77.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date of this dividend is Friday, June 28th. Humana's dividend payout ratio is presently 22.04%.

Insider Transactions at Humana

In other Humana news, Director Jorge S. Mesquita purchased 545 shares of the business's stock in a transaction that occurred on Tuesday, February 20th. The shares were bought at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the acquisition, the director now owns 2,578 shares in the company, valued at $946,358.02. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.32% of the company's stock.

Institutional Investors Weigh In On Humana

Institutional investors have recently modified their holdings of the business. Rakuten Securities Inc. purchased a new position in Humana in the 4th quarter worth approximately $25,000. Gradient Investments LLC raised its position in Humana by 200.0% in the fourth quarter. Gradient Investments LLC now owns 60 shares of the insurance provider's stock valued at $27,000 after purchasing an additional 40 shares during the period. Cetera Trust Company N.A acquired a new position in shares of Humana in the 4th quarter valued at $28,000. Private Wealth Management Group LLC purchased a new position in shares of Humana during the 4th quarter worth $32,000. Finally, Nvwm LLC increased its position in shares of Humana by 41.0% during the 3rd quarter. Nvwm LLC now owns 86 shares of the insurance provider's stock worth $42,000 after purchasing an additional 25 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.